Kang, Min Kyu
Park, Soo Yeun
Park, Jun Seok
Kim, Hye Jin
Kim, Jong Gwang
Kang, Byung Woog
Baek, Jin Ho
Cho, Seung Hyun
Seo, An Na
Kim, Duck-Woo
Kim, Jin
Baek, Se Jin
Kim, Ji Hoon
Kim, Ji Yeon
Ha, Gi Won
Park, Eun Jung
Park, In Ja
Kim, Chang Hyun
Kang, Hyun
Choi, Gyu-Seog
Funding for this research was provided by:
National R&D Program for Cancer Control through the National Cancer Center (NCC) funded by the Ministry of Health & Welfare, Republic of Korea (HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042, HA22C0042)
Article History
Received: 16 July 2023
Accepted: 4 September 2023
First Online: 3 November 2023
Declarations
:
: The study protocol, patient information, and consent were approved by the ethics committee of the Kyungpook National University Chilgok Hospital on October 17, 2019 and the IRBs of all participating institutions. Furthermore, the trial is approved by the Ministry of Food and Drug Safety (2020004284) on June 04, 2020. Patients will receive information (purpose, potential advantages, risks) about the study and be asked to sign a consent prior to enrolment. Each participant will complete written informed consent before enrollment. This study complies the principles of both Declaration of Helsinki rules and the Good Clinical Practices guidelines.
: Not Applicable.
: The authors declare no competing interests.